JEFFERSONVILLE, IN / ACCESSWIRE / April 17, 2024 / PharmaCord LLC, a leading provider of patient support services for the pharmaceutical industry, is pleased to announce the appointment of Rob Brown as Chief Growth Officer. Brown, who has been a part of the PharmaCord team since June 2021 and served as the Vice President of Strategic Accounts, will now oversee the business development and marketing teams, driving strategic initiatives to accelerate PharmaCord's growth trajectory. As Chief Growth Officer, Brown will develop and execute targeted business development initiatives, deliver innovative solutions, and further solidify PharmaCord's position as the preferred patient services partner.
JEFFERSONVILLE, IN / ACCESSWIRE / April 10, 2024 / PharmaCord LLC, a leading provider of patient support services for the pharmaceutical industry, is pleased to announce the appointment of Cindy Padgett as Chief Commercial Officer. In her new role, Padgett will be responsible for the commercialization of corporate and client initiatives, from solution design to customer experience optimization. As Chief Commercial Officer, she will oversee Solutions Development, Quality Operations, Legal Operations and Business Optimization and Standardization.
Inotiv is boosting its lab support services in cardiovascular and renal pharmacology, and CenExel Clinical Research is beefing up its dermatology capabilities.
After nearly five months off the market, the Massachusetts-based company said on Friday that it would lift its marketing hold for the blood disease treatment in Europe after the EU's Pharmacovigilance Risk Assessment Committee (PRAC) determined the drug's benefits outweigh its risks. The move will be effective immediately.
Expanded offerings will help regulated life science companies strengthen the supply chain for safe, quality medicines.
BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- Pear Therapeutics today announced the first participant enrolled in the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN)-0100 study on optimizing retention, duration, and discontinuation strategies for pharmacotherapy treatment of opioid use disorder (OUD), using Pear’s prescription digital therapeutic (PDT) reSET-O®. Investigators will study reSET-O, in conjunction with high- and standard-dose transmucosal buprenorphine, extended-release injectable buprenorphine, and extended-release injectable naltrexone in a multi-site randomized trial. The study is funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative. NIDA is part of the National Institutes of Health.
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced positive pharmacokinetic, tolerability and safety results from a Phase 1 trial of STS101. The Phase 1 data showed that all three dose strengths (5.2 mg and two higher dose strengths) administered with Satsuma’s improved second-generation nasal delivery device were well-tolerated and achieved the target pharmacokinetic profile. Based on results from this Phase 1 trial and other data, including preliminary results to date from the ongoing Phase 3 ASCEND long-term, open-label safety trial of STS101 5.2 mg, Satsuma is initiating its SUMMIT Phase 3 efficacy trial with the 5.2 mg dosage strength of STS101. As previously communicated, top-line results from the SUMMIT trial are expected in the second half of 2022.